ACCELERON POLICY ON CLINICAL TRIAL TRANSPARENCY

Our Commitment

At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Trust, honesty, and integrity are deeply important to how we operate.

Acceleron is committed to making information about our clinical research publicly available. We believe that timely disclosure of clinical study information is important to help advance medical research, inform patients and physicians, and engender greater public confidence in the safety of investigational and newly approved medicines.

Acceleron is committed to complying with applicable national and international laws, regulations, and principles for clinical trial disclosure and transparency, including those put forth by industry associations and supported by independent research organizations and editors of leading peer-reviewed journals.

The below outlines Acceleron's policy on Clinical Trial Transparency and the framework we follow in sharing clinical trial information with trial participants, family members and other caregivers, physicians, regulators, and independent researchers. We will continue to review and update this policy where appropriate as transparency regulations change and needs for open data sharing evolve.

Clinical Trial Registration

Acceleron registers required clinical trial information for Acceleron-sponsored clinical studies on applicable registries, including Clinicaltrials.gov, the EU Clinical Trials Register, and other registry websites in compliance with applicable global, regional, and local regulations and industry association principles.

Disclosure of Clinical Trial Results

The posting of summary results of Acceleron-completed trials to clinical trial registries is a fundamental element of our policy on clinical trial transparency. Results for all Acceleron interventional clinical trials, in accordance with applicable transparency laws and regulations, are made available on publicly accessible clinical trial registries such as Clinicaltrials.gov and the EU Clinical Trials Register, as well as local country registries where required (e.g., Spain REEC, Japan JAPIC). Acceleron is committed to making these results available within 12 months of trial completion, regardless of the outcome of the trial.

Sharing Clinical Trial Results with Patients

Acceleron is committed to providing trial summaries in a patient-friendly format that is easy to understand to our trial participants.

Publication in Peer-Reviewed Venues

Acceleron submits manuscripts for publication in peer-reviewed scientific and medical journals, which are subject to the peer-review process at the discretion of the journal editors. Acceleron will continue to ensure that clinical trial results of significant importance are submitted for consideration as abstracts during congresses and/or for publication in peer-reviewed journals, regardless if the results of the study

are positive or negative. This includes results from studies with investigational medicines whose development programs were discontinued.

Data Sharing with Researchers

Acceleron is working to adopt mechanisms for sharing de-identified patient-level datasets for approved products with qualified scientific and medical researchers. We are committed to developing a process that will enable us to receive, review, and fulfill requests for access to datasets for research proposals that demonstrate scientific merit and a purpose that promotes biomedical innovation. We will provide more information on our efforts around these activities as they evolve and will update this Policy on Clinical Trial Transparency accordingly.